Facebook
Twitter
LinkedIn
ForwardSEAAIS 2023 78th Annual Meeting
SEAAIS' 78th Annual Meeting is focused on the field of Allergy, Asthma and Immunology. It is directed to physicians, physician assistants, nurse practitioners and administrators. The purpose is to engage the audience through oral didactic presentations followed by group discussions. Each presentation is reflective of a need or interest of in-depth conversation or study requested by the membership and/or board. Case presentations are often utilized to solidify the objectives covered in each presentation.
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Southeastern Allergy, Asthma and Immunology Society (SEAAIS). The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 12.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 12.50 contact hours.
Commercial Support
This activity is supported in part by independent medical education grants from Merck, Takeda and CSL Behring.
Target Audience
Physicians
Physician Assistants
Nurse Practitioners
Administrators
Learning Objectives
At the conclusion of this meeting, learners should be able to…
1. Understand the upper and lower airway connection and learn the immunotherapy and remediations strategies for environmental asthma.
2. Review the signs of systemic mastocytosis and learn best practices diagnostic protocols and discuss new treatment options.
3. Analyze and evaluate the different treatments for patients with peanut allergy and summarize the new and emerging oral immunotherapy treatment options.
4. Learn the scope and cause of antibiotic resistance, discuss the benefits of testing for penicillin allergy and learn how to implement testing in your office.
5. Discuss how mast cells play a role in food allergy and learn how mast cell-dependent avoidance behavior in food allergy determines treatment and patient outcomes.
6. Examine the current diagnostic methods in testing and management of Eosinophilic Esophagitis from a gastroenterologist’s perspective and learn new treatment options.
7. Review diagnostic workup for HAE types 1 and 2 and learn current and emerging therapies for HAE.
8. Review the mechanism of IgE and discuss the role IgE plays in immunodeficiency.
9. Review biologic treatment options for asthma patients and learn how to choose the right treatment options for your patient.
10. Analyze and evaluate the different treatments for patients with CVID and summarize the new and emerging treatment options for CVID.
11. Discuss immune reactions to bites and stings and review venom immunotherapy updates.
12. Evaluate different cases related to GI food allergy, EoE and co-management from allergy/immunology and GI perspectives. Learn how the two specialties work together to improve patient outcomes.
13. Recognize the IgA response to food in the gut and learn what it means about tolerance vs. allergy.
14. Review clinical diagnostic parameters of severe pediatric asthma and discuss treatment and management of severe pediatric asthma.
15. Discuss current initiatives of the ACAAI advocacy council and learn recent legislation updates and what they mean for the practicing allergist/immunologist.
16. Review diagnostic criteria for alpha-gal syndrome and learn the latest updates in the treatment and management of alpha-gal.
Friday, September 22
7:30 – 8:00 AM BREAKFAST IN EXHIBITOR HALL
8:00 – 8:05 AM Welcome and Opening Remarks – Lee S. Clore, Jr., MD, Executive Secretary-Treasurer
8:05 – 8:45 AM Environmental asthma: immunotherapy & remediation strategies, John Carlson, MD
8:45 – 9:25 AM Systemic mastocytosis: state of the art in diagnosis and therapies, Patricia Lugar, MD
9:25 – 10:05 AM IgG response to peanut in oral immunotherapy, Robert Anthony, PhD
10:05 – 10:15 AM Question & Answer Session, Lee S. Clore, Jr., MD
10:15 – 10:45 AM BREAK IN EXHIBITOR HALL
10:45 AM – 11:25 AM Penicillin allergy evaluation in my clinic, Jack Eades, MD
11:25 – 12:10 PM Mast cell-dependent avoidance behavior in food allergy, Esther Borges Florsheim, PhD
12:10 – 12:55 PM LUNCH IN EXHIBITOR HALL
1:00 – 1:40 PM Current trends in management of EoE from a gastroenterologist’s perspective, Craig Reed, MD
1:40 – 2:20 PM HAE update, John Anderson, MD
2:20 – 2:30 PM Question & Answer Session, Lee S. Clore, Jr., MD
2:30 – 3:00 PM BUSINESS MEETING – Members Only Please
Saturday, September 23
7:30 – 8:00 AM BREAKFAST IN EXHIBITOR HALL
8:00 – 8:05 AM Welcome & Opening Remarks, Scott Commins, MD, President-Elect
8:05 – 8:45 AM Biology of IgE for experts, Robert Anthony, PhD
8:45 – 9:25 AM TfH cells in the ontogeny of IgE, Stephanie Eisenbarth, MD, PhD
9:25 – 10:05 AM How do I choose the right asthma biologic for my patients?, Joshua Kennedy, MD
10:05 – 10:15 AM Question & Answer, Scott Commins, MD
10:15 – 10:45 AM BREAK IN EXHIBITOR HALL
10:45 – 11:25 AM Update in CVID, Patricia Lugar, MD
11:25 AM – 11:55 AM Poster Symposium Set Up (Break from CME)
11:55 AM – 12:25 PM Poster Symposium Presentations (NON-CME), Scott Commins, MD
12:25 – 1:05 PM LUNCH IN EXHIBITOR HALL
1:10 – 1:50 PM Immune reactions to bites & stings – and venom IT updates, John Carlson, MD
1:50 – 2:30 PM Roundtable discussion of cases related to GI food allergy, EoE and co-management from A/I & GI perspectives, Dr. Reed, Florsheim, and others
2:30 – 2:40 PM Question and Answer Session, Scott Commins, MD
Sunday, September 24
8:15 – 8:20 AM Welcome & Opening Remarks
8:20 – 9:00 AM IgA responses to food in the gut and what it means about tolerance vs allergy, Stephanie Eisenbarth, MD, PhD
9:00 – 9:40 AM Management of severe pediatric asthma, Joshua Kennedy, MD
9:40 – 10:20 AM ACAAI advocacy and legislation update, J. Allen Meadows, MD
10:20 – 11:00 AM What’s the latest in alpha-gal syndrome?, Scott Commins, MD
11:00 – 11:10 AM Wrap up
Disclosure Policy and Disclosures
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewer, and other individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.
Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. (Examples of ineligible companies include: Advertising, marketing, or communication firms whose clients are ineligible companies; bio-medical startups that have begun a governmental regulatory approval process; compounding pharmacies that manufacture proprietary compounds; device manufacturers or distributors; diagnostic labs that sell proprietary products; growers, distributors, manufacturers or sellers of medical foods and dietary supplements; manufacturers of health-related wearable products; pharmaceutical companies or distributors; pharmacy benefit managers; reagent manufacturers or sellers).
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.
All relevant financial relationships with ineligible companies have been mitigated.
John Anderson, MD, Speaker
Advisor – CSL Behring, Takeda, Pharming, Biocryst, Ionis, Cycle Pharma, Pharvaris
Speaker – CSL Behring, Takeda, Pharming, Biocryst
Research – Takeda, Pharming, Biocryst, Biomatrix, Kalisa, Pharvaris
Robert Anthony, PhD, Speaker
Advisor – Nuvig Therapeutics
Lee S. Clore, Jr., MD, Planner
Advisor – Pharming
Speaker – AstraZeneca, GSK, Pharming, Sanofi Regeneron
Research – AstraZeneca, Eli Lilly, GSK, Novartis, Sanofi Regeneron, Escient
Scott Commins, MD, PhD, Planner, Speaker
Speaker – Genentech
Research – Revivicor
Jack Eades, MD, Speaker
Speaker – AstraZeneca, Pharming, Pfizer
Joshua Kennedy, MD, Speaker
Consultant – Genentech
Patricia Lugar, MD, Speaker
Advisor – Grifols
Speaker – Blueprint Medicines, Grifols
J. Allen Meadows, MD, Speaker
Advisor – Merck
Speaker – Optinose, Pfizer, Sanofi Regeneron, Teva
Research – DBV Technologies
Consultant - Takeda
The following have no relevant financial relationships with ineligible companies to disclose:
John Carlson, MD, Speaker
Stephanie Eisenbarth, MD, Speaker
J. Trent Ellenburg, DO, Planner
Ester Borges Florsheim, PhD, Speaker
Jean L. Owen, MBA, Planner
Available Credit
- 12.50 AMA PRA Category 1 Credit™
- 12.50 Attendance
- 12.50 CBRN